Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — SEB Enskilda Nordic Seminar 2009
30 slides from Getinge Ab Class B's conference presentation, Jan 8, 2009
Slide 1: SEB Enskilda Nordic Seminar
GETINGE SEB ENSKILDA NORDIC SEMINAR Copenhagen 8 January 2009
Slide 2: Agenda
BUSINESS AREA INFECTION CONTROL HEALTHCARE Agenda The Getinge Group Financial Review Year to date September 2008 Recent strategic developments Financial targets and drivers for growth and profitability
Slide 3: The Getinge Group
BUSINESS AREA INFECTION CONTROL HEALTHCARE The Getinge Group
Slide 4: Getinge Group net sales and presence
GETINGE GROUP Net Sales* 18 006 SEK Million Associates** 11 632 Sales companies 86 Factories 33 Agents 300 Infection Control Medical Systems Extended Care *) 12 months as of September 2008 **) 30 September, 2008
Slide 5: Infection Control: Sterilization, Disinfection
BUSINESS AREA INFECTION CONTROL Sterilization, Disinfection Production units 12 Sales companies 29 R&D costs, % of total sales 2,3 3% 23% 12% Europe USA & Canada 54% Asia & Australia 31% RoW Sales by business area Sales by geographic region 2008-09-30 2008-09-30
Slide 6: Infection Control products and solutions
PRODUCTS & SOLUTIONS BUSINESS AREA INFECTION CONTROL INFECTION CONTROL HEALTHCARE ISOLATOR ISOCYT FREJA Isolator for in-hospital preparation of pharmaceuticals for oncology Manufactured by the French company La Calhène HS66 TURBO STERILIZER Steam sterilizer used in hospitals and laboratories Signifi
Slide 7: Extended Care: Patient Handling, Hygiene, Wound Care
BUSINESS AREA EXTENDED CARE Patient Handling, Hygiene, Wound Care Production units 11 Sales companies 28 R&D costs, % of total sales 2,2 2% 9% Europe USA & Canada 28% Asia & Australia 61% RoW 34% Sales by business area Sales by geographic region 2008-09-30 2008-09-30
Slide 8: Extended Care products and solutions
PRODUCTS & SOLUTIONS BUSINESS AREA INFECTION CONTROL EXTENDED CARE HEALTHCARE Wound assist NPWT 0,8 Billion EURO fast growing segment in advanced wound care Intuitive – easy to use device Strong consumables trail Leverage European customer relationships MAXI MOVE A mobile patient lifter for demandin
Slide 9: Medical Systems: Surgical Workplaces, Cardiovascular, Critical Care
BUSINESS AREA MEDICAL SYSTEMS Surgical Workplaces, Cardiovascular, Critical Care Production units 10 Sales companies 29 R&D costs, % of total sales 8,2 8% 15% Europe 43% 45% USA & Canada Asia & Australia RoW 32% Sales by business area Sales by geographic region 2008-09-30 2008-09-30
Slide 10: Medical Systems: NAVA and Flow-i
PRODUCTS & SOLUTIONS BUSINESS AREA INFECTION CONTROL MEDICAL SYSTEMS HEALTHCARE NAVA New and unique method of synchronizing mechanical ventilation Installed base of Servo-i ventilators can be upgraded with NAVA Proprietary patient specific catheter Aim – Through clinical studies prove the reduced le
Slide 11: CARDIOHELP
PRODUCTS & SOLUTIONS BUSINESS AREA INFECTION CONTROL MEDICAL SYSTEMS HEALTHCARE CARDIOHELP Smallest portable heart-lung machine in the world CARDIOHELP will create new treatment options in intensive and emergency care Commercial launch H1 2009
Slide 12: Financial Review
BUSINESS AREA INFECTION CONTROL HEALTHCARE Financial Review Year to date September 2008
Slide 13: Development of organic order intake
FINANCIAL REVIEW YTD SEPTEMBER 2008 Development of organic order intake 2008 YTD MS EC IC TOT Europe 10% 4% -4% 4% USA and Canada 6% 14% 11% 11% Asia and Australia 10% 9% 9% 9% Rest of the world 48% 10% 80% 45% Total 12% 7% 4% 8% Adj for currency fluctuations and corporate acquisitions
Slide 14: Group results
FINANCIAL REVIEW YTD SEPTEMBER 2008 Group results 2008 2007 Change YTD YTD % Net sales 12 849 11 288 13,8% Gross margin 49,0% 46,0% Operating cost -4 514 -3 712 21,6% EBITA before restructuring 2 020 1 581 27,8% % 15,7% 14,0% Restructuring -147 -230 Financial net -547 -376 Profit before tax 1 089 87
Slide 15: Balance sheet items
FINANCIAL REVIEW YTD SEPTEMBER 2008 Balance sheet items 2008 2007 YTD YTD Operating cash flow 2 316 2 010 Net Debt 14 534 10 285 Equity 8 085 6 060 SEK Million
Slide 16: Maturity of debts
MATURITY OF DEBTS Q4 2009 2010 2011 2012 2013 2014 2015 Lender/Facility 2008 USA Private Placement 100 MUSD Nov 100 MUSD Nov 50 MUSD Nov Bridge Financing Datascope SEB 865 MUSD Mar Syndicated Credit Facility with 7 banks 332,5 MEUR Jun Jun Syndicated Credit Facility with 9 banks 810 MEUR Apr Nordic
Slide 17: Recent strategic developments
Recent strategic developments
Slide 18: Getinge strategic cornerstones
GETINGE STRATEGIC CORNERSTONES Global leadership We strive to be a global No 1 or No 2 in the product areas focused. Market leadership will help us attain cost leadership through scale. Solution provider We strive to combine the strength of our leading product positions and the depth of our know-how
Slide 19: The integration of Huntleigh
HUNTELIGH BUSINESSINTEGRATION AREA INFECTION CONTROL HEALTHCARE The integration of Huntleigh Cost synergies will exceed targeted 300 Msek p.a. New plant structure in place Joint sales and marketing organization under a single brand Improved logistics 3 PL Common IT Infrastructure 2009 – 2010 Revenue
Slide 20: Boston Scientific cardiac and vascular surgery acquisition
THE BOSTON SCIENTIFIC CARDIAC AND VASCULAR BUSINESS AREA INFECTION CONTROL SURGERY ACQUISITION HEALTHCARE Plans and actions in place to generate planned revenue synergies from 2009 onward Sales of revascularization products through Medical Systems existing sales channels on the OUS markets Sales of
Slide 21: Acquisition of Datascope: leading cardiovascular position
ACQUISITION OF DATASCOPE CORP. USA The acquisition of Datascope is consitent with Getinge’s ambition of building a leading Cardiovascular position with focus on: Cardiac Surgery Vascular Interventions Cardiac Assist (short – long term)
Slide 22: Datascope's share of counterpulsation therapy market
ACQUISITION OF DATASCOPE CORP. USA Datascope retains over 70 % of the global market for Counterpulsation therapy Intra Aortic Baloon Pumps Baloon Catheters Vascular Closure Devices
Slide 23: Datascope product portfolio and pipeline
ACQUISITION OF DATASCOPE CORP. USA Datascope has a strong product portfolio and a promising pipeline in the Endovascular Stent and Vascular Surgery market Vascular Grafts Peripheral Stents Stentgrafts
Slide 24: Financial targets and synergies
ACQUISITION BUSINESSOF DATASCOPE AREA CORP. INFECTION USA CONTROL HEALTHCARE Financial targets and synergies We expect revenue synergies from geographical and product complementarities to deliver organic top line growth of 10 % or better Elimination of duplication of sales infrastructure in 12 marke
Slide 25: Financial Targets and drivers for growth and profitability
BUSINESS AREA INFECTION CONTROL HEALTHCARE Financial Targets and drivers for growth and profitability
Slide 26: Group Financial targets
BUSINESS AREA INFECTION CONTROL HEALTHCARE Group Financial targets 15% year over year average growth of pre tax earnings Development of existing positions: 7–8% Acquisition of globally leading product lines: 7–8% To reach and maintain an EBITA-margin of 18-19 % (current structure) Cash flow generati
Slide 27: Growth Drivers
BUSINESS AREA INFECTION CONTROL HEALTHCARE Growth Drivers Getinge believes it can generate growth above market rates in the medium term Increased exposure to faster growing economies through investments in sales infrastructure in emerging markets Expansion of available market through product innovat
Slide 28: Drivers for expanding operating margins
BUSINESS AREA INFECTION CONTROL HEALTHCARE Drivers for expanding operating margins Cost based synergies from recent acquisition in combination with declining restructuring costs Initiatives to improve our existing supply-chain and structure Acquisition of businesses with higher operating margins
Slide 29: Next interim report
Next interim report 26 January, 2009
Slide 30: Questions & Answers
BUSINESS AREA INFECTION CONTROL HEALTHCARE Questions & Answers